Wire · operational-macro
Blood test for multiple cancers clears crucial hurdle on track to FDA approval
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 September 2026 · Fusion42 review
An FDA advisory panel has voted in favor of the Galleri blood test designed to detect multiple cancers early. The test has shown safety and promising accuracy in detecting cancer signals and their origin but still faces questions about its overall effectiveness and clinical impact.
This Wire brief sits within Fusion42's coverage of Health, and 9 sources have reported it between 23 Sep 2026 and 24 Sep 2026.
◆ ◆ The Wire takeaway
The FDA's likely approval of the Galleri test pushes multi-cancer blood screening from research to market access. You in healthtech must prepare for new competitive dynamics and clearer clinical adoption criteria.
◆ Coverage
9 sources · first reported 23 Sep 2026 · latest 24 Sep 2026
◆ Related on Wire
◆ Topics